SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) - A PROSPECTIVE, REAL-WORLD PHASE IV INTERVENTIONAL STUDY

被引：0
|
作者：
Rahmany, Sohail [1 ]
Young, David [1 ]
Moyses, Helen [2 ]
Gonclaves, Joao [3 ]
Latter, Sue [4 ]
Cummings, Fraser [1 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[2] Southampton Gen Hosp, NIHR Biomed Res Unit, Southampton, Hants, England
[3] Univ Lisbon, IMed Res Inst Med, Dept Pharm, Lisbon, Portugal
[4] Univ Southampton, Sch Hlth Sci, Southampton, Hants, England
来源：
GUT | 2023年 / 72卷 / SUPPL_2期
关键词：
D O I：
10.1136/gutjnl-2023-BSG.152
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P80
引用
收藏
页码：A92 / A93
页数：2
相关论文
共 50 条
  • [21] Use of subcutaneous and intravenous trastuzumab: Real-world experience from three hospitals in Sweden
    Valachis, A.
    Carlsson, L.
    Sundqvist, M.
    Li, B.
    Chiesa, F.
    Uhde, M.
    Sanglier, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy
    Wechsler, Robert T.
    Wheless, James
    Zafar, Muhammad
    Huesmann, Graham R.
    Lancman, Marcelo
    Segal, Eric
    Chez, Michael
    Aboumatar, Sami
    Patten, Anna
    Salah, Alejandro
    Malhotra, Manoj
    EPILEPSIA OPEN, 2022, 7 (02) : 293 - 305
  • [23] Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
    Clifton O. Bingham
    Shawn Black
    Natalie J. Shiff
    Stephen Xu
    Wayne Langholff
    Jeffrey R. Curtis
    Rheumatology and Therapy, 2023, 10 : 659 - 678
  • [24] Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
    Bingham, Clifton O.
    Black, Shawn
    Shiff, Natalie J.
    Xu, Stephen
    Langholff, Wayne
    Curtis, Jeffrey R.
    RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 659 - 678
  • [25] Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST) A real-world prospective interventional trial
    Masaki, Katsunori
    Suzukawa, Maho
    Sasano, Hitoshi
    Harada, Norihiro
    Miyazaki, Yasunari
    Katsura, Hideki
    Tagaya, Etsuko
    Terada, Junko
    Hojo, Masayuki
    Sugimoto, Naoya
    Nagase, Hiroyuki
    Kono, Yuta
    Hiranuma, Hisato
    Gon, Yasuhiro
    Takemura, Ryo
    Irie, Misato
    Nakamura, Reina
    Kabata, Hiroki
    Miyata, Jun
    Fukunaga, Koichi
    ALLERGOLOGY INTERNATIONAL, 2025, 74 (02) : 274 - 282
  • [26] Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data
    Guerra Veloz, M.
    Belvis Jimenez, M.
    Valdes Delgado, T.
    Castro Laria, L.
    Maldonado Perez, B.
    Benitez Roldan, A.
    Perea Amarillo, R.
    Merino Bohorquez, V.
    Calleja Hernandez, M. A.
    Caunedo Alvarez, A.
    Vilches Arenas, A.
    Arguelles-Arias, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S268 - S269
  • [27] SWITCHING TO BIOSIMILAR INFLIXIMAB: REAL-WORLD DATA FROM THE SOUTHAMPTON BIOLOGIC THERAPIES REVIEW SERVICE
    Holroyd, Christopher
    Parker, Lucy
    Bennett, Sarah
    Zarroug, Jalaa
    Underhill, Caron
    Davidson, Brian
    Armstrong, Ray
    Harvey, Nick
    Dennison, Elaine
    Cooper, Cyrus
    Edwards, Christopher J.
    RHEUMATOLOGY, 2016, 55 : 60 - 61
  • [28] Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
    Guerra Veloz, Maria Fernanda
    Belvis Jimenez, Maria
    Valdes Delgado, Teresa
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    Arguelles-Arias, Federico
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [29] An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
    D'Amico, Ferdinando
    Massimino, Luca
    Palmieri, Giulia
    Buono, Arianna Dal
    Gabbiadini, Roberto
    Caron, Benedicte
    Moreira, Paula
    Silva, Isabel
    Bosca-Watts, Maia
    Innocenti, Tommaso
    Dragoni, Gabriele
    Bezzio, Cristina
    Zilli, Alessandra
    Furfaro, Federica
    Saibeni, Simone
    Chaparro, Maria
    Garcia, Maria Jose
    Michalopoulos, George
    Viazis, Nikos
    Mantzaris, Gerassimos J.
    Ellul, Pierre
    Gisbert, Javier P.
    Magro, Fernando
    Peyrin-Biroulet, Laurent
    Armuzzi, Alessandro
    Ungaro, Federica
    Danese, Silvio
    Fiorino, Gionata
    Allocca, Mariangela
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (11)
  • [30] IS SWITCHING FROM IV TO SC ABATACEPT THERAPY SUSTAINABLE IN THE REAL WORLD? 1-YEAR ANALYSIS OF THE PROSPECTIVE, INTERNATIONAL ACTION STUDY
    Alten, R.
    Nuesslein, H.
    Galeazzi, M.
    Lorenz, H. M.
    Mariette, X.
    Cantagrel, A.
    Chartier, M.
    Elbez, Y.
    Rauch, C.
    Le Bars, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1030 - 1031
12345